Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
NCT03274011Phase 2Completed
- Sponsor
- Fudan University
- Start
- Jul 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Fudan University. Primary endpoint: Progression Free Survival at 12 weeks. Started Jul 2017; status: completed.
02
Drugs
Rivoceranib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03274011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03274011.